Browse the corpus

Biotinidase deficiency represents an autosomal recessive disorder that impairs the recycling of biotin, an essential coenzyme for 4 carboxylation enzymes: 3-methylcrotonyl-CoA carboxylase, pyruvate carboxylase, acetyl-CoA carboxylase, and propionyl-CoA carboxylase. Deficiency causes multiple carboxylase deficiency and disrupts amino acid, fatty acid, and gluconeogenesis pathways. The condition is classified as profound (0%-10% enzyme activity) or partial (10%-30% enzyme activity). Consanguinity is a major risk factor. Profound deficiency can present with developmental delay, seizures, hypotonia, alopecia, vision or hearing loss, ataxia, metabolic acidosis, and, without treatment, coma or death. Partial deficiency is often asymptomatic or associated with mild symptoms during stress. Diagnosis relies on newborn screening and confirmatory enzyme assay, which have markedly improved outcomes. Treatment consists of lifelong oral biotin supplementation, which prevents metabolic decompensation but may not reverse neurologic or sensory deficits, emphasizing the need for urgent detection and intervention. Prognosis is excellent with timely therapy. This activity for healthcare professionals is designed to enhance learners' competence in evaluating and managing biotinidase deficiency. Participants will deepen their understanding of the condition's etiology, risk factors, pathophysiology, clinical presentation, and best diagnostic and therapeutic practices. Improved skills will empower clinicians to collaborate successfully with interprofessional teams caring for individuals with this condition. Objectives: Identify the clinical features suggestive of biotinidase deficiency. Apply a stepwise diagnostic approach, including newborn screening interpretation, confirmatory enzyme assay, and genetic testing, to ensure timely and accurate diagnosis of biotinidase deficiency. Implement best practices for managing biotinidase deficiency and minimizing its complications. Collaborate with the interprofessional team to treat and monitor patients with biotinidase deficiency and educate affected families on genetic counseling, treatment adherence, and prognosis to optimize health outcomes. Access free multiple choice questions on this topic.

Vitamins are vital components of daily biochemical reactions and molecular processes. These substances function as cofactors, antioxidants, hormones, and mediators of vision. Vitamin deficiencies can result from inadequate dietary intake or abnormal intracellular processing. Biotin is an essential vitamin obtained from the diet and efficiently recycled for continued use. Failure of this recycling mechanism due to enzyme deficiency causes significant morbidity and mortality. Biotinidase deficiency, an autosomal recessive condition, is the most common cause. Biotin serves as a coenzyme for 4 carboxylation enzymes: 3-methylcrotonyl-CoA carboxylase (MCC), pyruvate carboxylase, acetyl-CoA carboxylase (ACC), and propionyl-CoA carboxylase (PCC). Biotinidase deficiency is classified as profound (0%-10% enzyme activity) or partial (10%-30% enzyme activity), with classification guiding the treatment approach. Clinical manifestations vary and may involve ophthalmologic, neurologic, dermatologic, and immunologic systems.[1][2] Partial cases are often asymptomatic or have mild symptoms, whereas profound cases may progress to seizures, developmental delay, vision or hearing loss, metabolic acidosis, and, without treatment, coma or death. Early recognition is critical, as prompt biotin supplementation can prevent or minimize irreversible complications.[3] Management is straightforward because patients require consistent, high doses of biotin. This intervention can reverse or halt the progression of many symptoms when initiated promptly. Early diagnosis and treatment can prevent developmental delay, reduce long-term disability, and improve quality of life.[4][5][6] Biotinidase deficiency is included in many newborn screening programs worldwide and in all 50 states in the U.S.[7][8][9] The therapeutic role of biotin in carboxylase deficiencies was first investigated approximately 40 years ago. In 1971, patients with β-methylcrotonylglycinuria, a carboxylase deficiency, demonstrated clinical response to biotin supplementation.[10] A decade later, Wolf et al identified a neonatal form of multiple carboxylase deficiency caused by biotin deficiency.[11][12]

Biotinidase deficiency follows an autosomal recessive inheritance pattern caused by 2 pathogenic variants in the BTD gene, located on chromosome 3p25.1. The BTD gene encodes the biotinidase enzyme, which recycles biotin and enables the cofactor to be available for carboxylase activity.[13] Biotinidase converts biocytin into free biotin by cleaving a lysine residue, thereby replenishing the biotin pool for subsequent reactions. In the absence of adequate biotin, carboxylase enzymes (MCC, ACC, PCC, and pyruvate carboxylase) cannot catalyze their reactions correctly, resulting in substrate accumulation that produces significant metabolic toxicity and clinical manifestations.

Biotinidase deficiency is a rare disorder with an incidence ranging from 1 per 40,000 to 1 per 60,000 births worldwide. In 2006, the incidence of profound cases was 1 per 80,000 births, and the incidence of partial cases ranged from 1 per 31,000 to 1 per 40,000 births in the U.S. The estimated carrier frequency is 1 in 123 individuals. Incidence rates vary by country.[14][15] Populations with higher rates of consanguinity demonstrate an increased incidence of biotinidase deficiency. This finding has been reported in Turkey and the Kingdom of Saudi Arabia. A higher incidence has also been observed in Hispanic infants born in the western U.S. and in Italian infants.[16][17][16] In contrast, a lower incidence has been reported in African-American populations. Newborn screening for biotinidase deficiency is now routinely performed in all U.S. states and in more than 25 countries worldwide.[18][19] Profound biotinidase deficiency typically manifests within the first 6 months of life, although the age of onset can vary.[20][21] Symptoms can appear as early as the 1st week of life and as late as age 10 years, with a mean age of onset of 3.5 months.

Biotin is a water-soluble B-complex vitamin. This micronutrient is present in several dietary sources, including milk, raw egg yolk, organ meats such as liver and kidney, Swiss chard, leafy green vegetables, and brewer’s yeast. Endogenous biotin is also synthesized by colonic flora within the large intestine. Apocarboxylase becomes holocarboxylase through biotin conjugation, a process mediated by holocarboxylase synthetase. Holocarboxylase undergoes proteolytic degradation, releasing biotinyl-peptides and biocytin. Biotinidase recycles biotin from these compounds, thereby replenishing the free biotin pool and maintaining its availability for carboxylases. Biotinidase deficiency results in insufficient free biotin for 4 critical carboxylases, leading to metabolic blocks in their respective pathways. Pyruvate carboxylase deficiency causes the accumulation of lactic acid and alanine. Reduced PCC activity leads to elevated propionate, 3-hydroxypropionate, and methylcitrate. Impaired MCC-mediated catalysis results in the buildup of 3-methylcrotonylglycine and 3-hydroxyisovalerate. ACC insufficiency causes acetyl-CoA accumulation. These combined biochemical abnormalities produce variable neurologic and dermatologic manifestations of biotinidase deficiency.

The extent of pathologic central nervous system findings in patients with biotinidase deficiency correlates with the severity of the clinical condition before death. The observed features resemble those of Wernicke encephalopathy or Leigh syndrome, although the pathologic brain lesions are more widespread. Myelin involvement appears pronounced compared with neuronal or axonal involvement. Necrotic lesions have been reported in the pons, hypothalamus, medulla, and hippocampus. Microscopic examination demonstrates microcavitation, gliosis, and capillary proliferation in affected regions. Extensive cerebral edema may also be present in many major white matter tracts.

Biotinidase deficiency is classified as either profound or partial. Individuals with less than 10% of normal enzymatic activity are diagnosed with profound biotinidase deficiency, whereas those with 10% to 30% activity are classified as having partial disease. This distinction is clinically important because prognosis and treatment differ between the 2 categories. Profound biotinidase deficiency typically presents in early infancy with variable neurologic and cutaneous manifestations. Neurologic findings may include seizures, hypotonia, ataxia, developmental delay, spastic paresis, and progressive visual impairment leading to optic atrophy in profound cases or optic neuropathy in partial cases.[22][23][24][23] Sensorineural hearing loss, lethargy, coma, and death may also occur if the condition is left untreated.[25] Cutaneous manifestations frequently include a skin rash, alopecia, conjunctivitis, and seborrheic dermatitis. Additional findings may include recurrent viral and fungal infections due to immune dysfunction, as well as respiratory manifestations such as apnea, tachypnea, or stridor. Metabolic derangements are common and may include ketolactic acidosis, organic aciduria, or hyperammonemia. Early detection and prompt biotin therapy render most symptoms reversible. Vision changes, hearing loss, and developmental delay are irreversible in profound cases if present.[26] Optic neuropathy in partial biotinidase deficiency may resolve with treatment. Untreated patients risk metabolic decompensation, coma, and death. Partial biotinidase deficiency can present anytime from infancy to adulthood. The manifestations may range from mild cutaneous findings, such as rash and alopecia, to severe neurologic manifestations, including seizures, hypotonia, and developmental delay. Symptoms typically occur during periods of physiologic stress, such as acute illness. Some individuals remain entirely asymptomatic throughout life.

Diagnosis of biotinidase deficiency is established through newborn screening or targeted testing of symptomatic patients. Enzyme activity is measurable in serum or plasma. When enzyme levels are abnormal, genetic testing may be performed to evaluate for BTD mutations.[27] Diagnosis is confirmed by demonstrating deficient biotinidase enzyme activity in serum or plasma or by identifying biallelic pathogenic or likely pathogenic BTD variants when enzymatic results are ambiguous. A consensus has not been established regarding standardized clinical diagnostic criteria for biotinidase deficiency. Laboratory findings may include elevated lactic acid and ammonia levels in blood or urine. Additional recommended investigations include arterial blood gas analysis, serum amino acid quantification, and serum chemistry panels. Urinary studies may include assessment for ketones and measurement of urinary organic acids. Brain magnetic resonance imaging in untreated patients during acute crisis frequently demonstrates diffuse cerebral and cerebellar T2-hyperintensity, cerebral swelling, bilateral compensatory ventriculomegaly, and delayed myelination.[28][29][30] Magnetic resonance spectroscopy provides functional information about brain metabolism. Although not widely available, this modality may help characterize brain pathology in vivo. Positron emission tomography can reveal changes in cerebral metabolic activity before and after biotin administration. Computed tomography may show bilateral basal ganglia calcifications that may not be detected on magnetic resonance imaging. Biotinidase deficiency should be considered in patients with recurrent fungal, viral, or skin infections.[31] Electroencephalography may demonstrate diffuse polyspike discharges or rhythmic diffuse spike-and-wave discharges. These findings typically normalize completely after biotin treatment. Ophthalmologic evaluation with dilated funduscopy is useful for detecting scotomata and optic nerve atrophy. Visual evoked potentials and visual field testing further delineate the extent of optic nerve involvement.

Treatment for biotinidase deficiency is lifelong but relatively straightforward. No formal clinical practice guidelines have been published. The recommended initial therapy is oral biotin replacement at a starting dose of 5 to 20 mg daily. Seizures and movement disorders typically improve within hours to days of treatment initiation. Cutaneous manifestations may require several weeks to resolve. If symptoms persist despite initial dosing, an increase to 40 mg daily is recommended. Children with developmental delays may regain previously lost milestones or acquire new ones. Recovery depends on the timing of treatment initiation and the degree of neurologic damage sustained prior to diagnosis. Treatment prevents further progression of irreversible neurologic damage.[32] Both symptomatic and asymptomatic patients should undergo audiologic evaluation, growth parameter assessment, and genetic counseling. Asymptomatic infants should also be evaluated by neurology to screen for hypotonia or seizures. Symptomatic patients require a more comprehensive assessment. Recommended evaluations include nutrition consultation, neurological examination, ophthalmologic evaluation, developmental assessment, detailed skin examination, immunologic history, and respiratory screening. Additional interventions may be indicated based on comorbidities or complications identified during these evaluations.

Biotinidase deficiency presents with a constellation of neurologic, dermatologic, and immunologic findings that closely resemble other inherited and acquired disorders. The differential diagnosis should thus include the following: Isolated carboxylase deficiency Dietary biotin deficiency Holocarboxylase synthetase deficiency Meningitis (seizures and rash) Primary immunodeficiency (fungal and bacterial infections) Sensorineural deafness Acrodermatitis enteropathica Autism (developmental delay and inattentiveness) Myelopathies Neuromyelitis optica Optic atrophy [33] Seborrheic dermatitis [34] Infantile spasms Vitamin B1 deficiency Neurocutaneous disorders Refsum disease Arsenic poisoning Inborn errors of metabolism Careful differentiation from these conditions is essential to ensure timely diagnosis and treatment. A systematic approach that integrates clinical evaluation, newborn screening results, confirmatory enzyme assays, and genetic testing is essential to diagnose biotinidase deficiency and distinguish it accurately from its mimics.

Biotinidase deficiency carries a favorable prognosis when identified early and managed with continuous care.[35] Inclusion of biotinidase deficiency in newborn screening programs has been instrumental in improving patient outcomes. Asymptomatic patients have an excellent prognosis when treatment is initiated before symptom onset. Symptomatic patients experience improvement in most clinical manifestations with pharmacologic biotin therapy. However, neurologic deficits present at the time of diagnosis are typically irreversible.[36]

Undetected and untreated biotinidase deficiency in infancy can result in severe and potentially irreversible complications, including optic neuropathy, acquired retinal dysplasia, and sensorineural deafness.[37] Neurologic sequelae, such as developmental disability and paresis, may arise. Metabolic derangements may include hyperammonemia or organic aciduria. Recurrent infections are common and may lead to significant morbidity. The condition can progress to coma and death in severe cases. Awareness of these complications underscores the importance of newborn screening and timely initiation of biotin therapy.

An interprofessional team approach is essential to achieve early diagnosis and initiate prompt treatment for biotinidase deficiency. Specialty consultations should include the following: Metabolic team/medical genetics Neonatology Nutrition Pediatrics Radiology Neurology Ophthamology Physiotherapy In pediatric patients, collaboration among a pediatric neurologist, geneticist, and metabolic disorder specialist is recommended for comprehensive evaluation and management.[38]

Families must understand that biotinidase deficiency requires lifelong and consistent treatment because the disorder involves a primary defect in the body’s ability to recycle biotin. Complications may be prevented through early diagnosis and management, but some manifestations remain irreversible. This disorder is inherited in an autosomal recessive manner. Consequently, families should receive counseling that the risk of having another affected child is 25% with each pregnancy involving the same 2 partners.

Early diagnosis and treatment of biotinidase deficiency are critical to reducing morbidity and mortality. Management requires a coordinated interprofessional team approach. Prompt evaluation by neonatologists, pediatricians, and geneticists is essential to prevent irreversible damage and complications in affected children. Biochemical metabolite studies confirm the diagnosis, and newborn screening programs in the U.S. and many other countries routinely include testing for biotinidase deficiency. Treatment must be initiated immediately upon detection and should not be delayed. Given the urgency of intervention, healthcare providers must be familiar with the clinical presentation and management strategies for biotinidase deficiency to ensure optimal patient outcomes. A coordinated interprofessional effort is essential for the diagnosis and management of biotinidase deficiency. The team should include physicians such as geneticists, pediatricians, neonatologists, and neurologists, along with advanced practitioners, therapists, nursing staff, and pharmacists. Detection typically occurs through newborn screening. The first providers to address an abnormal screen are usually pediatricians, neonatologists, or advanced practitioners. The healthcare team must recognize the symptoms, appreciate the urgency of treatment initiation, and promptly consult a medical geneticist. Under the guidance of the geneticist, treatment should be implemented without delay. Effective communication among all providers is critical to reducing morbidity and mortality. Radiologists may identify early brain changes that aid in diagnosis, particularly when the condition has been missed initially, and may help distinguish biotinidase deficiency from other brain and spinal cord disorders. Pediatricians and primary care physicians may detect partial biotinidase deficiency and must be able to recognize its clinical features. When neurological damage is present, physiotherapists play a role in treating hypotonia and developmental disability. Given the severe complications that may occur and the markedly improved outcomes with timely treatment, a coordinated interprofessional approach is necessary to optimize clinical outcomes and improve quality of life in affected children.